vTv Therapeutics Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On December 18, 2023, Chandresh Harjivan resigned as a member of the board of directors (the “Board”) of the Company to pursue other opportunities.
Extracted from this filing and checked against the source text.
Chandresh Harjivan resigned as member of the board of directors at vTv Therapeutics Inc..
On December 18, 2023, Chandresh Harjivan resigned as a member of the board of directors (the “Board”) of the Company to pursue other opportunities.View on SEC.gov
vTv Therapeutics Inc. terminated License Agreement between vTv Therapeutics LLC and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. valued at Notice of intent to terminate received on December 18, 2023; termination effective after negotiation (effective 2023-12-18).
On December 18, 2023, vTv Therapeutics LLC (“vTv LLC”), a controlled subsidiary of vTv Therapeutics Inc. (the “Company”), received notice from Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) of their intent to terminate the License Agreement between vTv LLC and Huadong, dated as of December 21, 2017, as amended January 14, 2021 (the “Agreement”).View on SEC.gov
38 material agreements filed in the last 30 days. Browse all material agreements →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.